Merck wins European approval for first-ever Ebola vaccine

(Reuters) - Merck & Co Inc on Monday received approval from the European Commission to market (http://bit.ly/2NZ0QMB) its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus. The vaccine, Ervebo, is approved for individuals aged 18 years and older and has already been used under emergency guidelines to try to protect against the spread of a deadly Ebola outbreak in Democratic Republic of Congo.